Surgical treatment of small bowel cancer: A 20-year single institution experience

被引:28
作者
Ito, H [1 ]
Perez, A [1 ]
Brooks, DC [1 ]
Osteen, RT [1 ]
Zinner, MJ [1 ]
Moore, FD [1 ]
Ashley, SW [1 ]
Whang, EE [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg,Small Bowel Ctr, Boston, MA 02215 USA
关键词
small bowel cancer; adenocarcinoma; sarcoma; carcinoid tumor;
D O I
10.1016/j.gassur.2003.07.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Small bowel malignancies are rare. The aims of this study were to evaluate the outcomes associated with surgical therapy for small bowel cancers and to define prognostic factors. The medical records of 96 consecutive patients with primary small bowel cancer (excluding lymphoma) treated at our institution over a 20 year period were reviewed. Survival was analyzed using the Kaplan-Meier method (mean follow-up period 5 7 months). Mean patient age was 56 years, and 58% of patients were male. Sixty percent of patients had an adenocarcinoma, 21% had a sarcoma, and 19% had a carcinoid tumor. The percentages of patients who underwent complete (curative) resection were 51%, 90%, and 50% for those with adenocarcinoma, sarcoma, and carcinoid tumor, respectively. For patients with adenocarcinoma who underwent curative resection, tumor (T) and node (N) stages were significant prognostic factors predicting overall survival. For patients with sarcomas who underwent curative resection, tumor grade was a significant prognostic factor predicting overall survival. The prognosis for patients with small intestinal carcinoid tumors is uniformly favorable. The prognosis for patients with sarcomas and adenocarcinomas is generally poor, although long-term survival is achieved by patients with favorable prognostic factors. (C) 2003 The Society for Surgery of the Alimentary Tract.
引用
收藏
页码:925 / 930
页数:6
相关论文
共 12 条
[1]   Adenocarcinoma of the small bowel - A study of 37 cases with emphasis on histologic prognostic factors [J].
Abrahams, NA ;
Halverson, A ;
Fazio, VW ;
Rybicki, LA ;
Goldblum, JR .
DISEASES OF THE COLON & RECTUM, 2002, 45 (11) :1496-1502
[2]  
*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN, P77
[3]   PRIMARY GASTROINTESTINAL SARCOMAS - ANALYSIS OF PROGNOSTIC VARIABLES [J].
CONLON, KC ;
CASPER, ES ;
BRENNAN, MF .
ANNALS OF SURGICAL ONCOLOGY, 1995, 2 (01) :26-31
[4]   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].
Demetri, GD ;
von Mehren, M ;
Blanke, CD ;
Van den Abbeele, AD ;
Eisenberg, B ;
Roberts, PJ ;
Heinrich, MC ;
Tuveson, DA ;
Singer, S ;
Janicek, M ;
Fletcher, JA ;
Silverman, SG ;
Silberman, SL ;
Capdeville, R ;
Kiese, B ;
Peng, B ;
Dimitrijevic, S ;
Druker, BJ ;
Corless, C ;
Fletcher, CDM ;
Joensuu, H .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480
[5]  
HOROWITZ J, 1995, J AM COLL SURGEONS, V180, P465
[6]  
Howe JR, 1999, CANCER-AM CANCER SOC, V86, P2693, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO
[7]  
2-U
[8]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[9]   Prognosis and survival in patients with gastrointestinal tract carcinoid tumors [J].
Shebani, KO ;
Souba, WW ;
Finkelstein, DM ;
Stark, PC ;
Elgadi, KM ;
Tanabe, KK ;
Ott, MJ .
ANNALS OF SURGERY, 1999, 229 (06) :815-821
[10]   Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors [J].
Singer, S ;
Rubin, BP ;
Lux, ML ;
Chen, CJ ;
Demetri, GD ;
Fletcher, CDM ;
Fletcher, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3898-3905